The Doctors Transitioned My Son at 13 - Here’s What Happened Next...
Melissa, the mother of Jonni Skinner, recounts how her son was placed on cross-sex hormones and puberty blockers from the age of thirteen after a social worker used the threat of suicide to override her parental doubts. Her testimony arrives as health authorities across Scandinavia and the Netherlands quietly dismantle the very protocols that shaped Jonni's treatment — making this episode essential listening for European clinicians, policymakers and families.
When Melissa first brought her teenage son to a gender clinic, she had questions — reasonable ones that any informed parent would raise. Those questions were answered with a threat: without medical transition, Jonni would not survive. What follows in this episode of Beyond Gender is a detailed, unflinching account of how a family was steered, pressured and ultimately harmed by a system that had substituted ideological certainty for cautious medicine. Social worker Sara Wiener introduced Melissa to a persuasion method familiar to parents across Europe: the suicide narrative. If your child does not receive hormones, she was told, the alternative is death. This framing, which researchers have increasingly criticised as pseudoscientific, does not merely motivate parents — it disables critical judgement at precisely the moment it is needed most. Melissa was also directed to a sex shop to purchase silicone breast forms and padded underwear, props intended to simulate the body Jonni was told he should inhabit. The clinical pathway had begun not with rigorous psychological assessment but with costume. The medical intervention that followed placed thirteen-year-old Jonni on oestrogen and spironolactone; puberty blockers were added to the regimen later. For European listeners following policy shifts in Sweden, Finland, France and the Netherlands, this sequence will be recognisable — it mirrors the treatment protocols that emerged from Amsterdam's pioneering work in the 1990s and spread across the Western world. Jonni experienced serious health consequences. When Melissa raised her concerns with the clinicians responsible for his care, they denied any connection between the medication and her son's worsening condition. That denial is a pattern now surfacing in testimonies on both sides of the Atlantic. Sweden's Karolinska Institute, Finland's COHERE and the Norwegian healthcare directorate have each concluded in recent years that the evidence base for paediatric gender medicine was far weaker than its proponents claimed. The Cass Review in Britain reached the same conclusion. What Melissa's account adds to this picture is texture: it shows how institutional pressure worked not in a policy document but in a consulting room, in the language used by one social worker on one frightened mother. Both Melissa and Jonni are now speaking publicly about what happened. Jonni's willingness to describe his own experience matters because the cohort of young people medically transitioned a decade ago is only beginning to find its voice, and their accounts are already shaping legislative and clinical responses across Europe. Parents sitting with similar doubts in German, Dutch or French gender clinics today are likely to hear versions of the same arguments Melissa encountered — the same urgency, the same dismissal of hesitation, the same assurance that the treatment is reversible. That assurance, as this episode makes plain, did not hold. The structural conditions that enabled this harm — rapid pathways to medical intervention, the sidelining of sceptical parents, practitioners operating well beyond what the evidence supports — remain in place across much of the continent. Jonni's story is not a historical footnote. It is a present warning.
